<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

3 min read

Fingers Crossed for a Market Recovery: Q123 Neuromodulation Market Recap

7/28/23 9:23 AM

Q123 Neuromodulation copyNeuromodulation companies are keeping their fingers crossed that the positive growth in Q123 is a sign that market recovery is well underway.  

With three of the four top neuromodulation companies reporting high-single-digit (HSD) growth in Q123, manufacturers are keeping their fingers crossed that market recovery is well underway. The impact of COVID has lessened significantly and several manufacturers reported that near-term improvement in healthcare staffing levels and post-COVID demand helped drive strong underlying procedure volumes in Q123. Competitors are also seeing gains on new and differentiated product offerings and expanded indications.

Among the many topics covered in detail in the comprehensive SmartTRAK Q123 Neuromodulation Market Recap* are:
  • Complete Q123 Neuromodulation Market Overview
  • SmartTRAK's Expert Market Analysis and Insights
  • All Neuro Companies' News, Revenues, Data, Charts and Market Shares
  • SCS On the Upswing
    • Products Contribute to Growth
    • New Competitor Enters the Market
    • Advancing New Indications, Reimbursement
  • Deep Brain Stimulation Sees Replacement Headwinds, Share Shifts
  • Q123 Clinical/Regulatory News

It’s too early to say whether or not the market is fully recovered or if the growth in the quarter is due to  ...

Read the entire Q123 Neuromodulation Market Recap, including SmartTRAK's expert analysis, news, data, charts, revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below. Learn More about Subscribing to SmartTRAK

SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.

Topics: Neuromodulation

Anne Staylor
Written by Anne Staylor

Former Senior Editor, Medtech Insight. +25 years in various leadership roles in business intelligence, marketing, communications, product management, and consulting for medical device industry, hospitals, physician groups, insurers. Registered nurse and former Director of Marketing for a national ambulatory surgery company.

  • There are no suggestions because the search field is empty.

Follow Us on Social Media

Recent Articles